InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,035.69
(
-1.57%
)
US TECH 100
16,929.60
(
-2.20%
)
Dow Jones
37,815.92
(
-1.49%
)
Brent Oil
85.94
(
-1.54%
)
Bitcoin
60,180.04
(
-5.73%
)
Post# of 251653
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1724
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: oc631 post# 251459

Tuesday, 04/16/2024 6:26:58 AM

Tuesday, April 16, 2024 6:26:58 AM

Post# of 251653

continued clinical advancement of the ex-vivo oncology construct CT-0525+Pembro in HER2+ solid tumors.



One clarification and a correction. The data for CAR-Monocyte CT-525 that will be released in Q4 will be monotherapy. After reviewing the CT-508/Pembro data the company fully believes a combination with a checkpoint inhibitor would be synergistic and they are moving in that direction. The program in liver fibrosis will be a engineered macrophage and not a CAR which makes the halting of CT-1119 even more of a mystery (to me).
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up